These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15603252)

  • 1. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS; Wengel J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.
    Wahlestedt C; Salmi P; Good L; Kela J; Johnsson T; Hökfelt T; Broberger C; Porreca F; Lai J; Ren K; Ossipov M; Koshkin A; Jakobsen N; Skouv J; Oerum H; Jacobsen MH; Wengel J
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5633-8. PubMed ID: 10805816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.
    Moschos SA; Frick M; Taylor B; Turnpenny P; Graves H; Spink KG; Brady K; Lamb D; Collins D; Rockel TD; Weber M; Lazari O; Perez-Tosar L; Fancy SA; Lapthorn C; Green MX; Evans S; Selby M; Jones G; Jones L; Kearney S; Mechiche H; Gikunju D; Subramanian R; Uhlmann E; Jurk M; Vollmer J; Ciaramella G; Yeadon M
    Mol Ther; 2011 Dec; 19(12):2163-8. PubMed ID: 21971426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards Zwitterionic Oligonucleotides with Improved Properties: the NAA/LNA-Gapmer Approach.
    Wojtyniak M; Schmidtgall B; Kirsch P; Ducho C
    Chembiochem; 2020 Nov; 21(22):3234-3243. PubMed ID: 32662164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.
    Wan WB; Migawa MT; Vasquez G; Murray HM; Nichols JG; Gaus H; Berdeja A; Lee S; Hart CE; Lima WF; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Dec; 42(22):13456-68. PubMed ID: 25398895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazole-linked Nucleic Acids: Synthesis, Therapeutics and Synthetic Biology Applications.
    Sharma VK; Mangla P; Singh SK; Prasad AK
    Curr Org Synth; 2024; 21(4):436-455. PubMed ID: 37138439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides.
    Riera-Tur I; Hinterdobler J; Maaske A; Sadewasser A; Schell M; Sekar J; Michel S; Klar R; Jaschinski F
    Nucleic Acid Ther; 2024 Jul; ():. PubMed ID: 39018509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4'-BNA/LNA with 9-(aminoethoxy)phenoxazine.
    Matsubayashi T; Yoshioka K; Lei Mon SS; Katsuyama M; Jia C; Yamaguchi T; Hara RI; Nagata T; Nakagawa O; Obika S; Yokota T
    Mol Ther Nucleic Acids; 2024 Jun; 35(2):102161. PubMed ID: 38978695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides.
    Pendergraff H; Schmidt S; Vikeså J; Weile C; Øverup C; W Lindholm M; Koch T
    Nucleic Acid Ther; 2020 Feb; 30(1):4-13. PubMed ID: 31618108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing.
    Nishina K; Piao W; Yoshida-Tanaka K; Sujino Y; Nishina T; Yamamoto T; Nitta K; Yoshioka K; Kuwahara H; Yasuhara H; Baba T; Ono F; Miyata K; Miyake K; Seth PP; Low A; Yoshida M; Bennett CF; Kataoka K; Mizusawa H; Obika S; Yokota T
    Nat Commun; 2015 Aug; 6():7969. PubMed ID: 26258894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts.
    Mook O; Vreijling J; Wengel SL; Wengel J; Zhou C; Chattopadhyaya J; Baas F; Fluiter K
    Artif DNA PNA XNA; 2010 Jul; 1(1):36-44. PubMed ID: 21687525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electronic Structures of LNA Phosphorothioate Oligonucleotides.
    Bohr HG; Shim I; Stein C; Ørum H; Hansen HF; Koch T
    Mol Ther Nucleic Acids; 2017 Sep; 8():428-441. PubMed ID: 28918042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POE Immunoassay: Plate-based oligonucleotide electro-chemiluminescent immunoassay for the quantification of nucleic acids in biological matrices.
    Thayer MB; Humphreys SC; Chung KS; Lade JM; Cook KD; Rock BM
    Sci Rep; 2020 Jun; 10(1):10425. PubMed ID: 32591626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
    Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
    Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.
    Elmén J; Thonberg H; Ljungberg K; Frieden M; Westergaard M; Xu Y; Wahren B; Liang Z; Ørum H; Koch T; Wahlestedt C
    Nucleic Acids Res; 2005; 33(1):439-47. PubMed ID: 15653644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of gene expression by gymnotic delivery of antisense oligonucleotides.
    Soifer HS; Koch T; Lai J; Hansen B; Hoeg A; Oerum H; Stein CA
    Methods Mol Biol; 2012; 815():333-46. PubMed ID: 22131003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.
    Stein CA; Hansen JB; Lai J; Wu S; Voskresenskiy A; Høg A; Worm J; Hedtjärn M; Souleimanian N; Miller P; Soifer HS; Castanotto D; Benimetskaya L; Ørum H; Koch T
    Nucleic Acids Res; 2010 Jan; 38(1):e3. PubMed ID: 19854938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locked nucleic acid oligonucleotides: the next generation of antisense agents?
    Grünweller A; Hartmann RK
    BioDrugs; 2007; 21(4):235-43. PubMed ID: 17628121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.
    Mook OR; Baas F; de Wissel MB; Fluiter K
    Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection.
    Zhang Y; Qu Z; Kim S; Shi V; Liao B; Kraft P; Bandaru R; Wu Y; Greenberger LM; Horak ID
    Gene Ther; 2011 Apr; 18(4):326-33. PubMed ID: 21179173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.